Gross-to-Net Product Sales and Significant Customers (Tables)

12 Months Ended

Dec. 31, 2017

Revenue, Net [Abstract]

Reconciliation of Gross to Net Product Sales

The below table presents a GTN product sales reconciliation for the accompanying Consolidated Statement of Operations:

	Year Ended December 31,
	2017			2016			2015
Gross product sales	$	245,797		$	244,770		$	215,136
Commercial rebates and government chargebacks	(105,148		)	(98,317		)	(61,283		)
Data and distribution fees, GPO fees, and inventory management fees	(20,083		)	(14,979		)	(15,613		)
Prompt pay discounts	(1,610		)	(755		)	(16		)
Product returns allowances	(2,778		)	(2,123		)	(1,373		)
Product sales, net	$	116,178		$	128,596		$	136,851

Schedule of Revenue by Major Customers by Reporting Segments

The below table presents the customers that represent 10% or more of our gross product sales in 2017, 2016, and 2015:

	Year Ended December 31,
	2017				2016				2015
AmerisourceBergen Corporation, and its affiliates	$	79,362	32.3	%	$	93,951	38.4	%	$	78,989	36.7	%
McKesson Corporation and its affiliates	76,363		31.1	%	75,952		31.0	%	73,577		34.2	%
Cardinal Health, Inc. and its affiliates	64,634		26.3	%	58,780		24.0	%	37,414		17.4	%
All other customers	25,438		10.3	%	16,087		6.6	%	25,156		11.7	%
Gross product sales	$	245,797	100.0	%	$	244,770	100.0	%	$	215,136	100.0	%

The below table presents our license fees and service revenue by source for the years ended December 31, 2017, 2016, and 2015:

	Year Ended December 31,
	2017				2016				2015
Out-license of FOLOTYN in all countries except the U.S., Canada, Europe, and Turkey: royalties (Note 16)	$	5,848	48.0	%	$	927	5.2	%	$	831	3.2	%
Out-license of ZEVALIN: recognition of upfront cash receipt and subsequent royalties for Asia and certain other territories, excluding China (Note 12)	1,245		10.2	%	1,756		9.8	%	15,144		58.9	%
Out-license of ZEVALIN: amortization of upfront cash receipt related to India territory (Note17(b)(iii)) and other	50		0.4	%	69		0.4	%	48		0.2	%
Out-license of ZEVALIN, FOLOTYN, BELEODAQ, MARQIBO: upfront cash receipt and subsequent royalties for the Canada territory (Note 17(b)(xv))	5		—	%	6,000		33.6	%	—		—	%
Out-license of ZEVALIN, MARQIBO, EVOMELA: upfront receipt for the China territory (Note 11)	—		—	%	—		—	%	9,682		37.7	%
Sales and marketing contracted services (Note 14)	4,747		38.9	%	9,096		51.0	%	—		—	%
Regulatory services provided to licensee	294		2.4	%	—		—	%	—		—	%
License fees and service revenues	$	12,189	100.0	%	$	17,848	100.0	%	$	25,705	100.0	%